KRRO - NASDAQ
Korro Bio, Inc.
$11.08
+2.1%Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
At a Glance
Live Snapshotkrro
Common Stock
Last Annual Value
9.00K
3-Year CAGR
%
5-Year CAGR
-23%
10-Year CAGR
-4%
Korro Bio, Inc. Competitors Analysis of Common Stock
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Korro Bio, Inc. NASDAQ:KRRO | 9.00K | 4.0% | -23.8% | N/A | |
 Alto Neuroscience, Inc. NYSE:ANRO | 3.00K | N/A | 24.6% | N/A | |
 Aura Biosciences, Inc. NASDAQ:AURA | 0.00 | N/A | N/A | N/A | |
 Larimar Therapeutics, Inc. NASDAQ:LRMR | 83.00K | 24.5% | 35.8% | 11.9% | |
 Altimmune, Inc. NASDAQ:ALT | 11.00K | 16.3% | 22.4% | 5.0% | |
 MBX Biosciences, Inc. Common Stock NASDAQ:MBX | 6.00K | 81.7% | N/A | N/A | |
 Quantum-Si incorporated NASDAQ:QSI | 22.00K | 16.3% | 9.5% | N/A | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 13.00K | 63.0% | 34.1% | N/A | |
 Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | 1.08M | 6.2% | 10.9% | 14.9% | |
 LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | 3.00K | 44.2% | N/A | N/A | |
 Annexon, Inc. NASDAQ:ANNX | 149.00K | 24.1% | 30.7% | N/A |
Korro Bio, Inc. Fair Value Envelope
Related Guides
Continue your KRRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.